Skip to main content
. 2023 Sep 9;6(4):240–252. doi: 10.1093/abt/tbad020

Figure 3.

Figure 3

Mechanism of action study showed that IMM47 antibody had strong blocking, ADCC, ADCP, ADCT and CDC activities. (A) Mechanism of action study: CD24 target blocking activity results showed that the IMM47 antibody had a strong ability to block the binding of Siglec-10 and CD24. (B) Mechanism of Action Study: ADCC activity results showed that the EC50 of IMM47 for ADCC of REH, Hela, MCF-7 and HCC1954 is 0.030, 0.162, 0.017 and 0.202 nM, respectively. (C) Mechanism of action study: ADCP activities (PBMC monocyte-induced macrophages) The results showed that IMM47 can significantly induce the phagocytosis of macrophages against Reh cells. The EC50 was 0.057 nM, and the phagocytic activity was significantly stronger than IMM01 (SIRPα-Fc fusion protein). (D) ADCP activity of PBMC-derived macrophage was observed by fluorescent microscope. The results showed that IMM47 can strongly induce the phagocytosis than MM01 against Reh cells. (E) Mechanism of action study: The ADCT assay results showed that IMM47 has strong ADCT activity with an EC50 of 0.333 nM against REH. The downregulation of CD24 on the surface of tumor cells reduces Siglec-10/CD24 signal transduction and enhances the attack of immune cells on tumor cells. (F) Mechanism of action study: CDC activity results showed that the EC50 of IMM47 against REH cells is 27.29 nM.